DERM Earnings Prediction
The chart below shows how DERM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DERM sees a +0.38% change in stock price 10 days leading up to the earnings, and a +2.33% change 10 days following the report. On the earnings day itself, the stock moves by -0.95%. This data can give you a slight idea of what to expect for the next quarter's release.
DERM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
14.86M
-13.49%
14.01%
Gross Margin
55.97%
2.19%
17.36%
Operating Margin
-19.70%
-24.98%
-74.56%
Net Margin
-22.63%
-53.53%
-71.76%
EPS
-0.17
-63.04%
-67.92%
No Data Available
DERM Earnings Analysis
Journey Medical Corporation Common Stock Corporation (DERM.O) Earnings Conference Call
Positive
- In Q2 2024, Journey Medical reported solid net product revenue of $14.9 million, demonstrating progress and putting them on track to meet their 2024 annual revenue guidance range of $55 million to $60 million.
- QBREXZA and Accutane, the core portfolio products, contributed $12.6 million in net product revenue for Q2, with both products gaining market share in their respective categories.
- The company achieved positive non-GAAP adjusted EBITDA of $300,000 in Q2, marking the fourth consecutive quarter of positive results, driven by strategic cost reductions and operational efficiency efforts.
- DFD-29, a product candidate for rosacea, has shown promising clinical trial results and potential market share opportunity in the $1.2 billion rosacea treatment market in the United States.
- Market research indicated strong adoption potential for DFD-29, with 79% of healthcare prescribers expressing willingness to prescribe the product and positive feedback from payers, indicating favorable negotiations for formulary inclusion and reimbursement upon approval.
- Journey Medical has a strong intellectual property portfolio with patent exclusivity until 2039 for key products, allowing for market exclusivity without generic intrusion and creating additional value through out-licensing opportunities and potential product acquisitions or in-licenses.
Negative
- Decrease in net product revenue from $17 million in Q2 of 2023 to $14.9 million in Q2 of 2024.
- Discontinuation of Aminolex at the end of Q3 in 2023 impacting revenue.
- Continued generic competition for target ox affecting revenue.
- Reduction in SG&A expense resulted from the rationalization of sales and marketing headcount.
- Conditional optimism expressed about the anticipated launch of DFD-29, dependent on FDA approval.
DERM FAQs
How does DERM typically perform around its earnings report dates?
Is Journey Medical Corporation (DERM) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DERM Earning Call Sentiment
Journey Medical Corporation (DERM) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
DERM.O
-1.6%Positive
The earnings call summary presents a mixed outlook. While there is a positive sentiment from the cost reduction initiatives, product launch preparation, and intellectual property strategy, concerns remain about competitive pressures, supply chain challenges, and ongoing financial risks. The lack of a shareholder return plan and the regulatory risk for DFD-29 approval further contribute to uncertainty. The Q&A session provided some positive insights regarding growth expectations but lacked clarity on SG&A guidance. Overall, the stock price is likely to remain stable, with potential fluctuations balancing out over the next two weeks.